Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome
Key facts
- Who runs it
- Tarsus University
- Where
- Mersin, TürkiyeSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 150 people, planned
- Started
- 15 May 2025
- Planned end
- 15 Apr 2026
- Type of study
- Observational
- Record updated
- 28 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Diagnosed with normal-mild-medium-severe OSAS
- 18 years and above
- Turkish speaking patients will be included
Who cannot take part
- Pregnancy,; Latent autoimmune diabetes,; Chronic renal failure,; Active or serious infections,; Liver failure,; Recent major cardiovascular events,; Unstable angina, heart failure (NYHA III-IV),; Patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests
Where in Türkiye
- Tarsus UniversityMersin, TürkiyeNo longer taking part
About the trial
What the trial wants to find out
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients.
Read full original descriptionShow less
This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
The group in the trial
- OSAS
Turkish-speaking patients diagnosed with normal-mild-moderate-severe OSAS, aged 18 and over, will be included.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 28 May 2025